Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer
A Correction to this paper has been published: https://doi.org/10.1038/s41419-020-03208-z
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-11-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-020-03208-z |